Top Markets
Coin of the day
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
Classificação em ações #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Preço da ação
$50.82
Última sincronização: 2026-08-11
Valor de mercado
$102.09M
Variação (1 dia)
1.90%
Variação (1 ano)
-
País
US
Negociar Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Categoria

Histórico de preços das ações de Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
Preço de fecho mais alto: $50.63 em 2026-08-01

Preço de fecho mais baixo: $27.02 em 2026-05-01
Histórico de preços das ações da Hemab Therapeutics Holdings, Inc. Common Stock de 2026 a 2026
Desempenho anual do preço das ações
Ano Desempenho
Não há dados suficientes para as datas fornecidas.
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH